UROLOGYTIMES.COM: Keyword Density Checker

Total words: 5536 | 2-word phrases: 1406 | 3-word phrases: 1618 | 4-word phrases: 1733

PAGE INFO

Title	Try to keep the title under 60 characters (77 characters) Urology Times \| News & Insights for Urologists & Health Professionals
Description	Try to keep the meta description between 50 - 160 characters (159 characters) Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Keywords	Meta keywords are not recommended anymore (159 characters) Urology Times
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	by hannah clarke	15	0.93%
2	in prostate cancer	14	0.87%
3	image credit ©	13	0.80%
4	by hannah clarkemay	11	0.68%
5	fda grants 510k	6	0.37%
6	tabletimage credit ©	5	0.31%
7	urology medical perspectives	4	0.25%
8	risk of recurrence	4	0.25%
9	disparities in prostate	4	0.25%
10	prostate cancer care	4	0.25%
11	lithotripsy and ultrasonic	4	0.25%
12	jason m broderick	4	0.25%
13	of prostate cancer	4	0.25%
14	prostate cancer progression	4	0.25%
15	genomic testing in	3	0.19%
16	of genomic testing	3	0.19%
17	oab and incontinence	3	0.19%
18	testing in prostate	3	0.19%
19	importance of genomic	3	0.19%
20	expert discusses advances	3	0.19%
21	case study highlights	3	0.19%
22	for tulsapro system	3	0.19%
23	discusses advances unmet	3	0.19%
24	needs across prostate	3	0.19%
25	of ab2100 in	3	0.19%
26	across prostate cancer	3	0.19%
27	pharmacologically treated bph	3	0.19%
28	12 trial of	3	0.19%
29	to show promise	3	0.19%
30	jason m broderickmay	3	0.19%

#	Keyword	Frequency	Density
1	disparities in prostate cancer	4	0.23%
2	in prostate cancer care	4	0.23%
3	in mcrpc by hannah	3	0.17%
4	holds potential in nmibc	3	0.17%
5	psmatargeted therapy in mcrpc	3	0.17%
6	clearance to ai companion	3	0.17%
7	to ai companion tool	3	0.17%
8	ai companion tool for	3	0.17%
9	companion tool for tulsapro	3	0.17%
10	expert discusses advances unmet	3	0.17%
11	tool for tulsapro system	3	0.17%
12	genomic testing in prostate	3	0.17%
13	apalutamide holds potential in	3	0.17%
14	prostate cancer by hannah	3	0.17%
15	of genomic testing in	3	0.17%
16	needs across prostate cancer	3	0.17%
17	importance of genomic testing	3	0.17%
18	health of female partners	3	0.17%
19	across prostate cancer continuum	3	0.17%
20	sexual health of female	3	0.17%
21	tool reveals impact of	3	0.17%
22	new tool reveals impact	3	0.17%
23	cancer by hannah clarke	3	0.17%
24	in prostate cancer by	3	0.17%
25	light cystoscopy decreases risk	3	0.17%
26	low testosterone and allcause	3	0.17%
27	decreases risk of recurrence	3	0.17%
28	benefit in prostate cancer	3	0.17%
29	is predictive of adt	3	0.17%
30	score is predictive of	3	0.17%
31	risk score is predictive	3	0.17%
32	cellcycle risk score is	3	0.17%
33	risk of recurrence progression	3	0.17%
34	between low testosterone and	3	0.17%
35	testosterone and allcause cvd	3	0.17%
36	tlx592 in prostate cancer	3	0.17%
37	and allcause cvd mortality	3	0.17%
38	of recurrence progression in	3	0.17%
39	to show promise in	3	0.17%
40	continues to show promise	3	0.17%

#	URL	Whois	Check
1	https://www.medicalworldnews.com/	Whois	medicalworldnews.com
2	http://jobs.modernmedicine.com/index.php?action=advanced_search&page=search&keywords=&mult_industries%5B%5D=Urologist&country=&zip_radius=&zip=&position_type=&min_salary=&max_salary=&salary_type=	Whois	modernmedicine.com
3	https://twitter.com/UrologyTimes	Whois	twitter.com
4	https://www.medicalworldnews.com/	Whois	medicalworldnews.com
5	http://jobs.modernmedicine.com/index.php?action=advanced_search&page=search&keywords=&mult_industries%5B%5D=Urologist&country=&zip_radius=&zip=&position_type=&min_salary=&max_salary=&salary_type=	Whois	modernmedicine.com
6	https://www.mjhlifesciences.com/contact	Whois	mjhlifesciences.com
7	http://jobs.modernmedicine.com/index.php	Whois	modernmedicine.com
8	https://www.facebook.com/UrologyTimes	Whois	facebook.com
9	https://twitter.com/UrologyTimes	Whois	twitter.com
10	https://www.linkedin.com/company/urology-times/	Whois	linkedin.com